Kalaris Therapeutics, Inc. (KLRS) — SEC Filings
Kalaris Therapeutics, Inc. (KLRS) — 40 SEC filings. Latest: EFFECT (Apr 14, 2026). Includes 20 8-K, 6 10-Q, 5 SC 13G/A.
View Kalaris Therapeutics, Inc. on SEC EDGAR
Overview
Kalaris Therapeutics, Inc. (KLRS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 14, 2026: Kalaris Therapeutics, Inc. filed an EFFECT form on April 14, 2026, indicating the effectiveness of a registration statement. The filing, with accession number 9999999995-26-001176, relates to Act 33 and File No. 333-294883. The effectiveness date was April 13, 2026.
Sentiment Summary
Across 40 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 34 neutral, 3 mixed. The dominant filing sentiment for Kalaris Therapeutics, Inc. is neutral.
Filing Type Overview
Kalaris Therapeutics, Inc. (KLRS) has filed 2 EFFECT, 20 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 2 SC 13G, 5 SC 13G/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (40)
Risk Profile
Risk Assessment: Of KLRS's 31 recent filings, 3 were flagged as high-risk, 17 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$11.894M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $42.387M |
| Operating Margin | N/A |
| Total Assets | $81.175M |
| Total Debt | N/A |
Key Executives
- Dr. Michael J. Yaszemski
- Dr. David L. Brown
- Srinivas Akkaraju, M.D., Ph.D.
- Andrew Oxtoby
- David L. Porter
- David L. Brown
- Steven M. Deitcher
- Dr. David M. Apelian
- Dr. David Apelian
- Dr. Ann M. D. M. Arvin
- Mr. David M. Rubinger
- Mr. Amaury Wittouck
- Abigail P. Johnson
Industry Context
Kalaris Therapeutics operates in the highly competitive biotechnology sector, focusing on developing novel therapies. The industry is characterized by long development cycles, significant R&D investment, and high regulatory hurdles. Success hinges on clinical trial outcomes and eventual market adoption against established and emerging competitors.
Top Tags
Biotechnology (4) · governance (4) · corporate-action (4) · 10-Q (4) · financials (3) · corporate-governance (3) · biotech (3) · institutional-ownership (3) · Clinical Trials (2) · Mergers and Acquisitions (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Effectiveness Date | 2026-04-13 | The date the registration statement became effective. |
| Filing Date | 2026-04-14 | The date the SEC accepted the filing. |
| Cash and Cash Equivalents | $42.387M | Increased from $1.639M at Dec 31, 2024, providing liquidity. |
| Net Loss (Q3 2025) | $11.894M | Reduced from $38.084M in Q3 2024, indicating improved operational efficiency or merger impact. |
| Net Loss (YTD Sep 2025) | $33.440M | Reduced from $47.141M in YTD Sep 2024, showing a narrowing of losses. |
| R&D Expenses (Q3 2025) | $9.126M | Decreased from $36.020M in Q3 2024, reflecting a shift in development focus or post-merger rationalization. |
| Additional Paid-in Capital | $191.858M | Significantly increased from $19.945M at Dec 31, 2024, primarily due to the AlloVir merger and equity conversions. |
| Common Stock Shares Outstanding | 18,702,418 | As of November 5, 2025, reflecting dilution from the merger and conversions. |
| Total Assets | $81.175M | Increased from $6.162M at Dec 31, 2024, largely due to increased cash and investments post-merger. |
| Net Loss (Q2 2025) | $11.35M | Increased from $5.65M in Q2 2024, indicating higher operating expenses. |
| Net Loss (YTD Q2 2025) | $21.55M | Increased from $9.06M in YTD Q2 2024, reflecting accelerated R&D and G&A spending. |
| Research and Development (Q2 2025) | $8.44M | Significantly increased from $3.21M in Q2 2024, showing increased investment in TH103. |
| General and Administrative (Q2 2025) | $3.82M | Increased from $976K in Q2 2024, partly due to merger-related and public company costs. |
| Cash and Cash Equivalents (June 30, 2025) | $88.43M | Substantial increase from $1.64M at Dec 31, 2024, primarily due to the AlloVir merger cash acquisition. |
| Cash Acquired from Merger | $102.11M | Key driver for the improved cash position, providing runway for operations. |
Forward-Looking Statements
- {"claim":"Allovir's stock (ALVR) will experience increased volatility and downward pressure.","entity":"ALVR","targetDate":"Q2 2024","confidence":"high"}
- {"claim":"Allovir will attempt to regain compliance with Nasdaq's minimum bid price rule, possibly through a reverse stock split.","entity":"Allovir, Inc.","targetDate":"Q3 2024","confidence":"medium"}
- {"claim":"Artal International S.C.A. will continue to be a significant institutional holder in AlloVir, Inc.","entity":"Artal International S.C.A.","targetDate":"Q2 2024","confidence":"high"}
- {"claim":"Allovir's stock price may experience downward pressure due to FMR LLC's reduced stake.","entity":"Allovir, Inc.","targetDate":"Within 3 months","confidence":"medium"}
- {"claim":"Other institutional investors might re-evaluate their positions in Allovir following FMR LLC's reduction.","entity":"Institutional Investors","targetDate":"Within 6 months","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Kalaris Therapeutics, Inc. (KLRS)?
Kalaris Therapeutics, Inc. has 40 recent SEC filings from Jan 2024 to Apr 2026, including 20 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of KLRS filings?
Across 40 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 34 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Kalaris Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Kalaris Therapeutics, Inc. (KLRS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Kalaris Therapeutics, Inc.?
Key financial highlights from Kalaris Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for KLRS?
The investment thesis for KLRS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Kalaris Therapeutics, Inc.?
Key executives identified across Kalaris Therapeutics, Inc.'s filings include Dr. Michael J. Yaszemski, Dr. David L. Brown, Srinivas Akkaraju, M.D., Ph.D., Andrew Oxtoby, David L. Porter and 8 others.
What are the main risk factors for Kalaris Therapeutics, Inc. stock?
Of KLRS's 31 assessed filings, 3 were flagged high-risk, 17 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Kalaris Therapeutics, Inc.?
Recent forward-looking statements from Kalaris Therapeutics, Inc. include guidance on {"claim":"Allovir's stock (ALVR) will experience increased volatility and downward pressure.","entity":"ALVR","targetDat and 4 other predictions.